Halstead Michael (Chief Executive Officer) bought $1.3M of stock
SEC Form 4
Helus Pharma Inc. is a US-listed company in the biotechnology industry. Its financial year ends in March.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Helus Pharma Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders4 buying, 0 selling9 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds57 adding, 22 cuttingOf 18 active managers that changed their stake, 15 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Share count rising (dilution): Diluted shares outstanding rose 72.1% year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Helus Pharma Inc.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 72.1% in a year.
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
Latest results
- Earnings per share
- -$1.26 against an average estimate of -$1.38: beat by 8.4%
- Next report
- November 12, 2026; average EPS estimate -$1.01
Price chart
- 1 day-16.9%
- 1 week-15.1%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-4.25
Growth
- Share count change
- +72.1%
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Insider trade
- Insider trade
So Eric H. L. (Executive Chair) bought $1.2M of stock
SEC Form 4 - Insider trade
Glavine Paul (Chief Growth Officer) bought $2.5M of stock
SEC Form 4 - Insider trade
So Eric H. L. (Executive Chair) bought $1.2M of stock
SEC Form 4 - Insider trade
Glavine Paul (Chief Growth Officer) bought $1.2M of stock
SEC Form 4 - Insider trade
So Eric H. L. (Executive Chair) bought $1.1M of stock
SEC Form 4 - Insider trade
Glavine Paul (Chief Growth Officer) bought $1.0M of stock
SEC Form 4
Valuation models
We value Helus Pharma Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Helus Pharma Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, before the open. Analysts expect revenue of $0 and EPS of −$1.01 (range −$1.30 to −$0.58) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$4.10 | +31% | — | 0% |
| Next | −$2.47 | +40% | $12m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −5.8% on 90 days ago. In the last 30 days, 0 analysts raised Helus Pharma Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$4.36 | −$3.29 |
| 60 days ago | −$3.71 | −$2.54 |
| 30 days ago | −$3.71 | −$2.54 |
| 7 days ago | −$3.72 | −$2.54 |
| Now | −$4.10 | −$2.47 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$1.38 | −$1.26 | +8.4% |
| Mar 2026 | −$1.14 | −$1.21 | −5.8% |
| Dec 2025 | −$0.98 | −$1.36 | −39.8% |
| Sept 2025 | −$1.33 | −$1.65 | −24.5% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- — of tradable shares
- Days to cover
- 1.71 at average volume
- Short interest, 1 month
- −7% to October 15, 2026
- Held by institutions
- 41% of shares
- Held by insiders
- 12.9% of shares
- Employees
- 100 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial statements
| Fiscal year | 2021 Mar 2021 | 2022 Mar 2022 |
|---|---|---|
| Income | ||
| Revenue | 1 | 0 |
| Gross profit | 0 | 0 |
| Net income | −24 | −54 |
| Diluted EPS | −$0.24 | −$0.32 |
| Growth (year on year) | ||
| Revenue | — | −100.0% |
| Margins | ||
| Gross margin | 23.1% | — |
| Net margin | <−999% | — |
| Free-cash-flow margin | <−999% | — |
| Cash flow | ||
| Cash from operations | −14 | −36 |
| Capital spending | 0 | 0 |
| Free cash flow | −15 | −36 |
| Stock-based pay | 9 | 14 |
| Free cash flow after stock pay | −23 | −51 |
| Balance sheet | ||
| Cash | 51 | 43 |
| Net debt (negative = net cash) | −51 | −43 |
| Diluted shares | 100m | 167m |
Financial health
- Short-term assets cover short-term liabilities $185m of assets due within a year against $19m of liabilities due within a year.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +72.1%
- year over year
Who owns it
Funds buying and selling- Reported value
- $198M
- Institutions reporting
- 98
- Shares held vs prior quarter
- ▲ 23.9%
- Positions opened / closed
- 28 / 8
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Venrock Adviser, LLC | $25.5M | 3.9M | 12.9% | 0.0% |
| Orbimed Advisors LLC | $21.6M | 3.3M | 10.9% | ▼ 14.6% |
| Adage Capital Partners Gp, L.L.C. | $20.2M | 3.1M | 10.2% | ▲ 337.1% |
| Millennium Management LLC | $17.4M | 2.6M | 8.8% | ▲ 9.0% |
| Rosalind Advisors, Inc. | $12.9M | 2.0M | 6.5% | ▲ 27.7% |
| Sphera Funds Management Ltd. | $10.7M | 1.6M | 5.4% | ▲ 64.2% |
| Acorn Capital Advisors, LLC | $10.2M | 1.5M | 5.2% | 0.0% |
| Dcf Advisers, LLC | $9.5M | 1.4M | 4.8% | ▲ 107.4% |
| Sio Capital Management, LLC | $8.6M | 1.3M | 4.3% | New |
| Nan Fung Group Holdings Ltd | $6.5M | 987K | 3.3% | ▲ 114.6% |
| Boxer Capital Management, LLC | $5.2M | 790K | 2.6% | ▲ 23.4% |
| Logos Global Management LP | $5M | 750K | 2.5% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Helus Pharma Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $9.7M 9 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $9.7M net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Cavers Greg Chief Financial Officer | September 29, 2026 | Buy | 3,000 | $12.91 | $38,730 |
| Halstead Michael Chief Executive Officer | September 21, 2026 | Buy | 100,000 | $13.47 | $1.3M |
| So Eric H. L. Executive Chair | September 8, 2026 | Buy | 100,000 | $12.39 | $1.2M |
| Glavine Paul Chief Growth Officer | September 8, 2026 | Buy | 100,000 | $12.47 | $1.2M |
| Glavine Paul Chief Growth Officer | September 8, 2026 | Buy | 100,000 | $12.47 | $1.2M |
| So Eric H. L. Executive Chair | September 4, 2026 | Buy | 100,000 | $12.09 | $1.2M |
| Glavine Paul Chief Growth Officer | September 3, 2026 | Buy | 100,000 | $11.78 | $1.2M |
| So Eric H. L. Executive Chair | September 1, 2026 | Buy | 95,000 | $11.81 | $1.1M |
| Glavine Paul Chief Growth Officer | August 31, 2026 | Buy | 90,000 | $11.59 | $1M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Helus Pharma Inc. in brief
- What does Helus Pharma Inc. do?
- Helus Pharma Inc. is a US-listed company in the biotechnology industry. Its financial year ends in March.
- What is Helus Pharma Inc.'s stock ticker?
- Helus Pharma Inc. trades under the ticker HELP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Helus Pharma Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Venrock Adviser, LLC, Orbimed Advisors LLC and Adage Capital Partners Gp, L.L.C. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Helus Pharma Inc. stock?
- Over the last 12 months, Helus Pharma Inc.'s directors and officers reported 9 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
- When is Helus Pharma Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Helus Pharma Inc. announces its own schedule.
Follow research on Helus Pharma Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.